Results 101 to 110 of about 24,588 (279)

Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N‐ERD Patients

Clinical &Experimental Allergy, EarlyView.
Dupilumab therapy reduced elevated type 2 cytokine responses post‐ASA provocation in N‐ERD patients, independent of ASA tolerance, and revealed novel mechanistic insights by modulating acute type 2 immunity. Transcriptomic analysis showed concurrent downregulation of lipid and peroxisome pathways during ASA challenge in N‐ERD patients after 24 weeks of
Julia Eckl‐Dorna, Christina Morgenstern, Katharina Poglitsch, Tamara Arnoldner, Katharina Gangl, Tina J. Bartosik, Nicholas J. Campion, Aldine Tu, Victoria Stanek, Sven Schneider, Christine Bangert   +10 more
wiley   +1 more source

Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium

ERJ Open Research, 2019
Background Guidelines recommend omalizumab in patients with uncontrolled severe allergic asthma. We investigated real-life use of omalizumab, the proportion of patients fulfilling eligibility criteria, its costs and its effectiveness.
Katia M.C. Verhamme, Catherine Lucet, Alain Van Meerhaeghe, Guy G.O. Brusselle, Marie-Laurence Lambert   +4 more
doaj   +1 more source

Estudio de utilización de omalizumab y mepolizumab en asma refractaria grave [PDF]

, 2018
Introducción. En los últimos años, se han comercializado diferentes fármacos biológicos dirigidos a dianas específicas del asma, como el omalizumab y mepolizumab.
López Cárdenas, Mª Teresa
core  

Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma

, 2019
Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma.
Bousquet, Jean, Brusselle, Guy, Buhl, Roland, Katsaounou, Paraskevi, Martinez, Rafael, Pfister, Pascal, Wahn, Ulrich   +6 more
core   +1 more source

Use of electronic medical records and biomarkers to manage risk and resource efficiencies [PDF]

, 2017
Peer reviewedPublisher ...
Blakey, John, Chisholm, Alison, Kocks, Janwillem W H, Lisspers, Karin, Price, David, Ryan, Dermot, Ställberg, Björn, The Respiratory Effectiveness Group, Thomas, Mike   +8 more
core   +7 more sources

Development of a Conjugate Vaccine Targeting Human IgE for Long‐Term Prevention of Anaphylaxis

Allergy, EarlyView.
Vincent Serra, Laurent L. Reber
wiley   +1 more source

Modifiable Risk Factors for Symptom Burden in Chronic Rhinosinusitis With Nasal Polyps: The Role of Obesity and Sleep Apnoea

Clinical Otolaryngology, EarlyView.
ABSTRACT Objective To identify sociodemographic and clinical predictors of symptom severity and quality of life (QoL) impairment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), diagnosed according to the latest EPOS 2020 criteria. Study Design Cross‐sectional analytical study.
Javier Modesto García‐Fernández, María Soledad Sánchez‐Torices, María Pilar Gómez‐Gallego, Miguel Ángel Feliz‐Fernández, María Alharilla Montilla‐Ibáñez, Rafael Lomas‐Vega   +5 more
wiley   +1 more source

A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database

Scientific Reports
Omalizumab is a biologic agent used in the management of allergic conditions, including asthma and urticaria. Although the efficacy of omalizumab has been well established, its safety profile is primarily derived from clinical trials with limited sample ...
Yongfu Song, Zhuang Wang, Na Wang, Xiaofei Xie, Tieshi Zhu, Yongji Wang   +5 more
doaj   +1 more source

Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature

Case Reports in Dermatology, 2012
Omalizumab is a recombinant humanized monoclonal antibody that blocks the high-affinity Fc receptor of IgE. Omalizumab has been approved for the treatment of moderate to severe asthma; however, there is currently more and more data showing promising ...
Ilya Ivyanskiy, Carsten Sand, Simon Francis Thomsen   +2 more
doaj   +1 more source

Allergy for a Lifetime? [PDF]

, 2010
As the key molecule of type-I-hypersensitivity, IgE provides specificity for the allergen and links it to the allergic effector functions. Antibodies are secreted by plasma cells and their precursors, the plasma blasts.
Luger, Elke O., Wegmann, Michael, Achatz, Gernot, Worm, Margitta, Renz, Harald, Radbruch, Andreas   +5 more
core   +3 more sources